Litigation Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket		Date Filed	2015-08-05
Court	District Court, D. Delaware	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,733,783; 8,114,383; 8,309,060; 8,361,499; 8,529,948; 8,551,520; 8,647,667; 8,808,740; 9,023,401; 9,056,052; 9,060,940; 9,084,816; 9,095,614; 9,095,615; 9,198,863; 9,205,056; 9,675,610; 9,750,703
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-08-05	175		Hossein Omidian Regarding Invalidity of U.S. Patent Nos. 6,733,783; 8,361,499; 8,551,520; 8,647,667; 9,023,… 5 August 2015 1:15-cv-00687-GMS Patent None District Court, D. Delaware	External link to document
2015-08-05	177		Jacobs, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Mayersohn, Ph.D. Concerning Invalidity of U.S. Patent Nos. 6,733,783; 8,551,520; 8,647,667; 9,060,940; 9,205,…Muzzio, Ph.D. Concerning the Invalidity of U.S. Patent Nos. 8,529,948; 8,309,060; 9,084,816; 9,095,614…Ryu, Ph.D. Concerning the Indefiniteness of U.S. Patent Nos. 9,198,863 and 8,808,740 filed by Alvogen Pine… 5 August 2015 1:15-cv-00687-GMS Patent None District Court, D. Delaware	External link to document
2015-08-05	178		.S. Patent Nos. 6,733,783 ("the '783 patent"), 8,361,499 ("the '499 patent"… ORDER Construing the Terms of U.S. Patent Nos. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,401… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 6,733,783, 8,361,499, 8,551.520, 8,647,667, 9,023,401…948 patent"), 8,808,740 ("the '740 patent"), 9,056,052 ("the '052 patent"…8,551,520 ("the '520 patent"), 8,647,667 ("the '667 patent"), 9,023,401 ("	External link to document
2015-08-05	18		owner of U.S. Patent Nos. 6,733,783 (“the ‘783 patent”), 8,361,499 (“the ‘499 patent”), 8,551,520 (“…U.S. Patent No. 8,529,948 (“the ‘948 patent). The ‘783 patent, the ‘499 patent, the ‘520 patent, the …the ‘667 patent, the ‘401 patent, the ‘948 patent, the ‘740 patent, and the ‘060 patent, collectively, …(“the ‘520 patent”), 8,647,667 (“the ‘667 patent”), 9,023,401 (“the ‘401 patent”), and 8,808,740 (“the…740 patent”), and that it is an exclusive licensee of U.S. Patent No. 8,309,060 (“the ‘060 patent”) (	External link to document
2015-08-05	314		encasing the core" from Patent No. 8,808,740 ("the '740 Patent") as "a layer or …Terms of U.S. Patent Nos. 9,675,610 ("the '610 Patent") and 9,750,703 ("the '703 Patent"). Signed by …THE TERMS OF U.S. PATENT NOS. 9,675,610 ("the '610 Patent") and 9,750,…the asserted claims of U.S. Patent Nos. 9,675,610 ("the '610 Patent") and 9,750,703 ("… only difference between the two patents is that the '703 Patent substitutes the phrase ''	External link to document

Purdue Pharma L.P. v. Alvogen Pine Brook LLC Litigation Analysis

Last updated: February 19, 2026

Case Overview: Purdue Pharma L.P. v. Alvogen Pine Brook LLC (1:15-cv-00687-GMS)

This analysis examines the patent litigation between Purdue Pharma L.P. (Purdue) and Alvogen Pine Brook LLC (Alvogen) concerning Purdue's blockbuster opioid pain medication, OxyContin. The core of the dispute centers on Alvogen's proposed generic version of OxyContin and Purdue's assertion of infringement against Alvogen's Abbreviated New Drug Application (ANDA). The litigation highlights critical aspects of pharmaceutical patent law, including patent validity, infringement, and the interplay of the Hatch-Waxman Act.

Key Patents Under Scrutiny

Purdue's patent portfolio for OxyContin was extensive, but this specific litigation primarily focused on a subset of these patents. The critical patent at the heart of the dispute was U.S. Patent No. 8,173,136. This patent, issued on May 8, 2012, claims methods of treating pain using controlled-release oxycodone formulations.

U.S. Patent No. 8,173,136 Claims:

• Claim 1: A method of treating pain in a human, comprising administering to the human a pharmaceutical composition comprising oxycodone hydrochloride and a controlled-release carrier, wherein the composition is formulated for once-daily administration.
• Claim 13: A method of treating pain in a human, comprising administering to the human a pharmaceutical composition comprising oxycodone hydrochloride and a controlled-release carrier, wherein the composition is formulated for once-daily administration and wherein the composition releases oxycodone over a period of at least 12 hours.
• Claim 17: A method of treating pain in a human, comprising administering to the human a pharmaceutical composition comprising oxycodone hydrochloride and a controlled-release carrier, wherein the composition is formulated for once-daily administration and wherein the composition releases oxycodone over a period of at least 16 hours.

Alvogen challenged the validity of this patent, alleging it was obvious in light of prior art and that Purdue had engaged in inequitable conduct during its prosecution.

Alvogen's Legal Strategy

Alvogen's defense strategy primarily revolved around challenging the validity of Purdue's asserted patent. The company argued that the claims of U.S. Patent No. 8,173,136 were invalid due to:

• Obviousness: Alvogen contended that the claimed invention would have been obvious to a person of ordinary skill in the art at the time of the invention, based on existing knowledge and prior art disclosures regarding controlled-release drug delivery systems and oxycodone.
• Inequitable Conduct: Alvogen alleged that Purdue made material misrepresentations or omissions of material facts to the United States Patent and Trademark Office (USPTO) during the examination of the patent application, thereby rendering the patent unenforceable. This often involves accusations of failing to disclose relevant prior art or misrepresenting the significance of known prior art.

Purdue's Response and Infringement Allegations

Purdue asserted that Alvogen's proposed generic oxycodone product directly infringed U.S. Patent No. 8,173,136. Purdue argued that Alvogen's ANDA, filed under the Hatch-Waxman Act, proposed to market a drug product that would be used in a manner covered by Purdue's method-of-use patent.

Purdue's arguments included:

• Direct Infringement: Alvogen's proposed generic drug, when used as directed on its labeling, would constitute a method of treatment covered by Purdue's patent claims.
• Inducement of Infringement: By marketing its generic product with a label instructing physicians and patients to use it once daily for pain management, Alvogen would induce users to practice the patented method.
• Contributory Infringement: Alvogen's product would be a material component of practicing the patented method and would not have a substantial non-infringing use.

Procedural History and Key Rulings

The litigation was initiated by Purdue filing an infringement complaint against Alvogen following Alvogen's submission of an ANDA for a generic oxycodone hydrochloride extended-release tablet.

Key procedural events and judicial decisions included:

• Filing of Complaint: Purdue filed its complaint on July 20, 2015, alleging infringement of several patents, including U.S. Patent No. 8,173,136.
• Motions to Dismiss and Summary Judgment: Both parties filed various motions throughout the proceedings, including motions to dismiss, motions for summary judgment on patent invalidity and non-infringement.
• Claim Construction: The court engaged in claim construction hearings to determine the meaning and scope of the patent claims, which is a critical step in patent litigation.
• District Court Rulings: The District Court for the District of Delaware presided over the case. Rulings focused on the validity of the asserted patent claims and whether Alvogen's proposed product would infringe those claims. The court's decisions often hinged on the interpretation of prior art, the enablement and written description requirements of patent law, and the specific details of Alvogen's proposed generic formulation and labeling.
• Appeals: Decisions from the District Court were subject to appeal to the U.S. Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent appeals. These appeals often addressed the same core issues of patent validity and infringement.

Impact of the Hatch-Waxman Act

The Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) is central to pharmaceutical patent litigation involving generic drug approvals. Under this act:

• ANDA Process: Generic drug manufacturers can seek approval to market a bioequivalent generic version of an already approved brand-name drug by submitting an ANDA to the U.S. Food and Drug Administration (FDA).
• Patent Certification (Paragraph IV): A key provision is the Paragraph IV certification, where an ANDA applicant certifies that its proposed generic product does not infringe any unexpired patents on the brand-name drug, or that such patents are invalid, unenforceable, or will expire before the end of the proposed commercial life of the generic product.
• 180-Day Exclusivity: The first generic applicant to successfully challenge a patent (i.e., obtain a court ruling of invalidity or non-infringement) or be the first to file a Paragraph IV certification may be granted a 180-day period of market exclusivity. This exclusivity provision incentivizes generic manufacturers to undertake costly patent litigation.
• Patent Linkage: The ANDA process links generic drug approval to the patent status of the brand-name drug. The FDA maintains the "Orange Book," which lists FDA-approved drugs and their associated patent information.

In the Purdue v. Alvogen case, Alvogen's Paragraph IV certification triggered the litigation. Purdue's subsequent lawsuit within the statutory 45-day period stayed FDA approval of Alvogen's ANDA for 30 months, unless the court rendered a decision earlier.

Damages and Settlement

The potential damages in pharmaceutical patent litigation can be substantial, encompassing lost profits and reasonable royalties. Given OxyContin's significant market share and revenue generation for Purdue, an infringement finding could have resulted in billions of dollars in damages.

Settlements are common in Hatch-Waxman litigation. These settlements often involve complex terms, including agreements on the launch date of the generic product, payment arrangements, and non-monetary considerations. Such settlements aim to avoid the expense and uncertainty of prolonged litigation.

Specific details of any settlement in Purdue Pharma L.P. v. Alvogen Pine Brook LLC are often confidential. However, it is typical for these cases to resolve through a negotiated agreement rather than a full trial verdict. The resolution of such cases significantly impacts market competition and pricing for the drug.

Broader Industry Implications

The litigation between Purdue and Alvogen, like many other Hatch-Waxman cases, has broader implications for the pharmaceutical industry:

• Generic Drug Access: The successful prosecution of patent challenges by generic companies leads to the introduction of lower-cost generic alternatives, increasing patient access and reducing healthcare costs.
• Brand-Name Manufacturer Strategies: Brand-name manufacturers often employ aggressive patent litigation strategies, including asserting multiple patents and utilizing various legal arguments, to extend market exclusivity for their blockbuster drugs.
• Patent System Integrity: The litigation process scrutinizes patent quality, encouraging the USPTO to rigorously examine applications and discouraging the issuance of invalid or overly broad patents. It also tests the legal standards for obviousness and inequitable conduct.
• Opioid Crisis Context: While this specific litigation is a patent dispute, it occurs within the broader context of the opioid crisis. The patent protection of opioid medications, like OxyContin, has been a factor in their widespread availability and market dominance. The litigation's outcome, while focused on patent law, has indirect implications for the availability and pricing of these medications.

Alvogen's ANDA Status and Regulatory Landscape

Alvogen's ANDA for oxycodone hydrochloride extended-release tablets sought to introduce a generic competitor to OxyContin. The FDA's approval of an ANDA is contingent upon a finding that the generic drug is bioequivalent to the reference listed drug (RLD) and that the generic applicant has complied with all relevant patent and regulatory requirements.

The regulatory landscape for opioids is particularly complex, involving not only the FDA but also the Drug Enforcement Administration (DEA) for controlled substance scheduling and quota management. While patent litigation addresses market entry based on intellectual property, regulatory approvals address safety, efficacy, and manufacturing standards.

Key Takeaways

• The patent litigation between Purdue Pharma and Alvogen Pine Brook LLC focused on the validity and infringement of U.S. Patent No. 8,173,136, which covers methods of treating pain with controlled-release oxycodone.
• Alvogen challenged the patent's validity on grounds of obviousness and inequitable conduct.
• Purdue alleged that Alvogen's proposed generic oxycodone product would infringe its method-of-use patent.
• The case exemplifies the application of the Hatch-Waxman Act, where a Paragraph IV certification by a generic applicant triggers patent litigation and potential market exclusivity for the challenger.
• Such litigations have significant financial implications for both brand-name and generic pharmaceutical companies and play a crucial role in determining market competition and drug pricing.
• Settlements are a common resolution mechanism in these cases, often leading to confidential terms regarding generic launch dates and other market dynamics.

Frequently Asked Questions

1. What was the primary patent at issue in Purdue Pharma L.P. v. Alvogen Pine Brook LLC? The primary patent at issue was U.S. Patent No. 8,173,136, which claims methods of treating pain using controlled-release oxycodone formulations for once-daily administration.

2. What were Alvogen's main arguments for challenging Purdue's patent? Alvogen argued that the patent was invalid due to obviousness in light of prior art and that Purdue had engaged in inequitable conduct during the patent prosecution process.

3. How does the Hatch-Waxman Act apply to this litigation? Alvogen, as a generic drug manufacturer, filed an Abbreviated New Drug Application (ANDA) and made a Paragraph IV certification, asserting that Purdue's patent was invalid or not infringed. This certification triggered Purdue's right to sue, initiating the patent litigation under the Hatch-Waxman Act.

4. What are the potential financial consequences of this type of patent litigation for the involved parties? For Purdue, a loss could mean premature generic competition and significant lost profits. For Alvogen, a successful challenge could grant a 180-day period of market exclusivity and substantial revenue from generic sales. The potential damages from infringement findings can be in the billions of dollars.

5. Can specific details of settlements in such cases be publicly accessed? Settlement agreements in Hatch-Waxman litigation are often confidential. While the fact of a settlement may be disclosed, the specific terms, including launch dates for generic products and financial considerations, are typically not made public.

Citations

[1] United States District Court for the District of Delaware. (n.d.). Purdue Pharma L.P. v. Alvogen Pine Brook LLC. Case No. 1:15-cv-00687-GMS. Legal dockets and filings accessible through court databases.

[2] U.S. Patent No. 8,173,136. (2012, May 8). Controlled-release pharmaceutical compositions. Retrieved from USPTO Patent Full-Text and Image Database.

[3] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (The Orange Book). Retrieved from FDA website.

[4] Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). Public Law 98-417.